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Chronic myeloid leukemia (CML) is a malignant 
cancer derived from hematopoietic stem cells. CML is 
induced by an oncogenic BCR-ABL1 fusion protein, 
which has constitutive tyrosine kinase activity. The 
BCR-ABL1 fusion protein is produced from the fused 
Philadelphia chromosome formed by the translocation 
of chromosomes 9 and 22 [1]. Multiple pharmaceutical 
companies have developed specific inhibitors of the BCR-
ABL1 tyrosine kinase inhibitor (TKI). Imatinib, the first 
generation of such TKIs, has been used to treat CML [2]. 
Although imatinib could treat many patients with CML, 
some CML cells have developed resistance to imatinib. 
Resistance to imatinib allows CML to progress from the 
initial chronic phase (CP) to the late advanced blast phase 
(BP) [3]. To treat such resistant CML, a second-generation 
TKI, nilotinib, was developed. However, CML has 
developed resistance to nilotinib as well. Multiple studies 
have revealed that resistance to TKIs, including nilotinib, 
could be BCR-ABL-dependent [4] and -independent [5]. 
BCR-ABL-dependent resistance typically results from a 
point mutation or amplification of BCR-ABL. However, 
the mechanism by which BCR-ABL-independent 
resistance to TKI develops is still not clearly understood. 
In a recent study published in Leukemia, we found that 
the expression of Cobll1 was strongly correlated to drug 
resistance and blastic transformation in CML [6]. We 
revealed a novel mechanism involving Cobll1 for TKI 
resistance and progression of CML to BP. Cobll1 was 
found to be selectively overexpressed in BC cells from the 
bone marrow and peripheral blood in paired or relapsed 
CML patients. The expression of Cobll1 is dependent 
on the progression of CML to the BP. The importance of 
Cobll1 in TKI resistance was proved by the significant 
increase in TKI resistance in CML cells in the CP with 
ectopic expression of Cobll1 and the re-sensitization of 
CML cells in the BP by Cobll1 knockdown. Consistently, 
the survival rate of CML patients in the BP with high 
Cobll1 expression was lower than that of CML patients in 
the BP with low Cobll1 expression. These results indicated 
that Cobll1 is an important factor for determining the 
survival of CML patients in the BP. Furthermore, we 
demonstrated that Cobll1 was highly expressed in CD34+/
CD38- or CD34+/CD38+ primitive stem cell populations 
from CML patients in the BP. Consistently, we found that 
the zebrafish paralog, Cobll1b, was important for normal 
hematopoiesis during embryonic development. The high 
levels of Cobll1 during CML progression appears to 
be achieved by an increase in Cobll1 mRNA, which is 
strongly correlated with the downregulation of miR-424 
and miR-503 during CML progression. Consistently, when 
miR-424 or miR-503 was overexpressed in K562 cells, 
Cobll1 was significantly reduced, and the cells become 
sensitive to nilotinib. Increased Cobll1 in CML stabilizes 
IKKg to activate the NF-kB signaling pathway, leading to 
nilotinib resistance and progression to BP. The model for 
Cobll1 function is as follows (Figure 1). High levels of 
Cobll1 expression promotes the transformation of CML 
and generates drug resistance by increasing IKKγ stability, 
which results in the activation of the canonical NF-κB 
pathway. The importance of Cobll1 in CML progression 
and TKI resistance revealed in our recent studies suggests 
a novel Cobll1-targeting strategy for treating TKI-
resistant CML. However, some unanswered questions 
need to be addressed before such a novel strategy can be 
developed: (i) Can there be a small molecule targeting 
Cobll1 function? (ii) Half the BC cells in the study were 
Cobll1-negative. What are the pathway(s) that regulate BC 
progression and TKI resistance in these cells? (iii) How 
is miR-424, which controls the expression of Cobll1, 
increased in BC?
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Figure 1: Model of drug resistance and progression in 
CML
Oncotarget90627www.impactjournals.com/oncotarget
Correspondence to: Dong-Wook Kim, email dwkim@catho-
lic.ac.kr
Hongtae Kim: Department of Biological Science, 
Sungkyunkwan University, Suwon, Republic of Korea
Correspondence to: Hongtae Kim, email khtcat@skku.edu
Keywords: Cobll1, CML, TKI, BP, HSC
Received: August 30, 2017
Published: October 10, 2017
REFERENCES
1. Deininger MW, et al. Blood. 2000; 96:3343-3356. 
2. Melo JV, et al. Nat Rev Cancer. 2007; 7:441-453.
3. O’Brien SG, et al. N Engl J Med. 2003; 348:994-1004.
4. Soverini S, et al. Clin Cancer Res. 2006; 12:7374-7379.
5. Donato NJ, et al. Blood. 2003; 101:690-698.
6. Han SH, et al. Leukemia. 2017; 7:1532-1539. 
Copyright: Kim et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and re-
production in any medium, provided the original author and source 
are credited.
